Immunotherapy targeting the CLTA4 protein in HCV-related HCC demonstrated modest extended survival in a disease that has a high mortality rate.
Despite HCC having a poor prognosis and high mortality, systemic antiangiogenesis therapies offer some hope to patients.
Forming a multidisciplinary clinic for patients with HCC resulted in improved survival, likely due to more streamlined care and earlier diagnosis, found research presented at SSO 2013.
Radiofrequency ablation might offer comparable survival rates when compared with liver surgery for patients with hepatocellular carcinoma.
Aspirin use, but not the use of other nonsteroidal anti-inflammatory drugs (NSAIDs), is associated with a reduced risk of developing hepatocellular carcinoma.
Patients with advanced unresectable hepatocellular carcinoma have a higher median overall survival when treated with drug eluting bead transarterial chemoembolization.
Drug-eluting beads are a new type of drug delivery system that may be able to decrease side effects and localize chemotherapy treatment in HCC patients.
The first patient has been treated in a phase 2 clinical trial of intravenous delivery JX-594 in patients with advanced hepatocellular carcinoma.
In a randomized phase 3 trial, first-line brivanib did not meet its primary overall survival end point in patients with hapatocellular carcinoma.
A cohort study of Danish patients with alcoholic cirrhosis suggests that because they are at low risk for hepatocellular carcinoma (HCC), "surveillance would be expected to have a minimal effect on mortality and is unlikely to be cost effective,"
The investigators sought to understand the relationships between familial clustering of hepatocellular carcinoma (HCC), family history of liver cancer and the incidence of hepatitis.
Danish researchers have established a link between childhood obesity and hepatocellular carcinoma (HCC) in adults.
Loco-regional therapy with selective internal radiation therapy (SIRT) and sorafenib demonstrated good efficacy in patients with advanced hepatocellular carcinoma (HCC), especially those in Barcelona Clinic Liver Criteria (BCLC) stage B.
The search for a drug that can treat many different forms of cancer may be over. This comes with news that Isis Pharmaceuticals has initiated a Phase 1 study targeting the expression in tumors of signal transducer and activator of transcription 3 (STAT3), a gene that is ubiquitous and overexpressed in many tumor types.
Transarterial chemoembolization (TACE) with sequential sorafenib delayed time to progression (TTP) of intermediate-stage hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection, a prospective randomized study concluded in The Oncologist online February 14.
This patient information fact sheet provides information on the basics relating to the liver and the causes of and treatments for liver cancer.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|